GSK to reveal data from diabetes drug from HGS amid hostile bid; Royalty Pharma finds $600M to finance biotech deals;

@FierceBiotech: FDA panel mixed on Pfizer's rare disease drug. More | Follow @FierceBiotech

@RyanMFierce: Bloomberg: After dubious Sirtris deal, Glaxo has targeted partners in recent M&As. Report | Follow @RyanMFierce

@JohnCFierce: EMA recommends Vertex's Kalydeco for cystic fibrosis population. Item | Follow @JohnCFierce

> GlaxoSmithKline ($GSK) is revealing late-stage data on a potential GLP-1 drug for diabetes, albiglutide, which the London-based drug giant is developing in partnership with Human Genome Sciences ($HGSI), the target of GSK's hostile takeover bid. Article

> The European Medicines Agency's Committee for Medicinal Products for Human Use has signed off on approval of GlaxoSmithKline's ($GSK) drug Votrient for treating patients with certain types of soft tissue sarcoma. Release

> New York-based Royalty Pharma had raised $600 million from a debt deal to bankroll purchases of royalty rights on experimental and marketed drugs. Item

> Elan boss: Climate improved for Alzheimer's drugs. Article

> Sangart stashes $50M funding for oxygenation drugs. News

> GSK gambles on biotech partners after dubious M&A deal. More

Pharma News

@FiercePharma: Watson asks for FDA approval on generic Testim, Auxilium's testosterone drug. Auxilium sues (of course). Story | Follow @FiercePharma

> House could vote on FDA bill next week. Report

> EMA continues Pradaxa support but wants clearer warnings. Article

> Takeda takes buying binge into Brazil with $265M Multilab deal. Item

> Ranbaxy brings in U.S. consultants as part of consent decree. News

Devices News

@FierceMedDev: The Senate passed the FDA user fee bill 96-1, a move praised by members of the device industry. Story | Follow @FierceMedDev

@MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> FCC approves spectrum bandwidth for medical devices. Report

> Led by Medtronic, hypertension devices could pay big in the U.S. News

> NEJM study: IUDs, implants prevent more unwanted pregnancies. More

> MIT concocts next-generation, needle-free drug injector. Article

And Finally… Scientists might have found a new way to predict volcanic eruptions using crystals. Article

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.